Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(3):255-260
Infectious complications of pancreatic cysts (PC) is one of the problem of modern medicine due to insufficient data on pharmacokinetic of majority of antimicrobials resulting to the lack of standards for antimicrobial therapy and prophylaxis of this disorder. One of the promising options for the treatment and prophylaxis of PC-associated infections is moxifloxacin, but there is no data available on its pharmacokinetic in PC. Twenty eight PK samples and 27 serum samples from 27 patients with PK cysts were included in the study. Samples were obtained 3 hours after 400 mg IV dose of moxifloxacin. Drug concentrations were measured using reversed-phase high performance liquid chromatography. All calculations were done using Millennium v2.1 software. Moxifloxacin concentrations in PCs were 0.04–1.98 mg/l (mean±SD = 0.57±0.41). Corresponding serum concentrations were 0.86-2.45 mg/l (mean ± SD = 1.67±0.39). In general, PC concentrations of moxifloxacin were lower than serum concentrations, but still higher than MICs for majority of bacterial pathogens. Moreover, no bacterial growth was detected in all PC samples and no clinical signs of infections were registered. Thus, it can be concluded that moxifloxacin may be an interesting option for the therapy and prophylaxis of PC-associated infections.